In re ACTOS Antitrust Litigation

CourtDistrict Court, S.D. New York
DecidedMarch 30, 2022
Docket1:13-cv-09244
StatusUnknown

This text of In re ACTOS Antitrust Litigation (In re ACTOS Antitrust Litigation) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re ACTOS Antitrust Litigation, (S.D.N.Y. 2022).

Opinion

USL SUNT

UNITED STATES DISTRICT COURT ELECTRONICALLY FILED SOUTHERN DISTRICT OF NEW YORK DOC □ DATE FILED:__ 3/30/2022 __ IN RE ACTOS ANTITRUST LITIGATION THIS DOCUMENT RELATES TO: Master File No. 1:13-cv-09244 (RA) (SDA) ALL ACTIONS OPINION AND ORDER

STEWART D. AARON, United States Magistrate Judge: Pending before the Court is Plaintiffs’ Letter Motion seeking to compel Defendants Takeda Pharmaceutical Co. Ltd., Takeda America Holdings, Inc., Takeda Pharmaceuticals U.S.A., Inc. and Takeda Development Center Americas, Inc. (collectively, “Defendants” or “Takeda”) to (1) produce all nonprivileged, responsive earlier-in-time emails that are part of the most-inclusive email threads Takeda already has produced or will produce to Plaintiffs; and (2) provide privilege log entries for earlier-in-time emails that are part of email threads redacted or withheld for privilege. (Pls.” 3/22/22 Ltr. Mot., ECF No. 359.) For the reasons set forth below, Plaintiffs’ Letter Motion is GRANTED IN PART and DENIED IN PART. BACKGROUND This is a complex antitrust class action in which Plaintiffs allege that the Takeda prevented competitors from timely marketing a generic version of Takeda’s diabetes drug ACTOS by falsely describing two patents to the Food and Drug Administration. See In re Actos End-Payor Antitrust Litig., 848 F.3d 89, 92 (2d Cir. 2017). Plaintiffs are drug purchasers who allege that they wrongfully were obliged to pay monopoly prices for ACTOS from January 2011, when Takeda’s patent on the

active ingredient in ACTOS expired, to at least February 2013, when the mass of generic market entry occurred. See id. This action was filed on December 31, 2013. (See Compl., ECF No. 1.) On March 18, 2015,

the Court approved the Order Governing Protocol for Discovery of Electronically Stored Information and Hard Copy Documents (the “Discovery Protocol”) that the parties had proposed. (See Discovery Protocol, ECF No. 193.) The Discovery Protocol calls for the production of electronically stored information (“ESI”) in native format, together with the metadata and coding fields set forth in Exhibit 1 to the Protocol. (See id. at 6-7 & Ex. 1.) The Protocol requires the parties to de-duplicate the ESI that is produced, so as to avoid the production of “exact duplicate

documents.” (See id. at 4-5.) However, the Protocol nowhere provides for the production of only the most inclusive email threads. (See generally Discovery Protocol.) After motion practice and two appeals to the Second Circuit, on August 25, 2021, the Circuit remanded this action to this Court. See United Food & Com. Workers Loc. 1776 & Participating Emps. Health & Welfare Fund v. Takeda Pharm. Co. Ltd., 11 F.4th 118, 138 (2d Cir.

2021) Beginning in February 2022, Takeda made multiple rolling productions of non-privileged documents from 25 agreed custodians, including six in-house lawyers. (See Pls.’ 3/22/22 Ltr. Mot. at 1; Defs.’ 3/25/22 Opp., ECF No. 362, at 1.) In its production, Takeda used email threading, “by which a party reviews and produces the most-inclusive email in a thread.” (See Defs.’ 3/25/22 Opp. at 3.) Plaintiffs object to Takeda’s use of email threading and seek to compel Takeda to

produce what they refer to as “earlier-in-time emails,” as well as the metadata associated with those emails. (See Pls.’ 3/22/22 Ltr. Mot. at 3; Pls.’ 3/28/22 Reply, ECF No. 366, at 3.) Plaintiffs also seek to compel Takeda to provide privilege log entries for all emails, including the earlier-in-time emails. (See Pls.’ 3/22/22 Ltr. Mot. at 2; Pls.’ 3/28/22 Reply at 1-2.) Takeda responds that compelling such an approach “would impose an enormous burden.” (See

Defs.’ 3/25/22 Opp. at 2.) The parties have exchanged drafts of a privilege log protocol, but have been unable to agree to the terms. (See Defs.’ 3/25/22 Opp., Ex. 1.) The Court held a telephone conference on March 29, 2022, during which Plaintiffs’ Letter Motion was addressed. DISCUSSION I. Email Threading

The first issue before the Court, i.e., regarding email threading, highlights the importance of negotiating a comprehensive ESI protocol before data production is undertaken. The issue arises here because Takeda made its initial rolling productions using email threading even though the Discovery Protocol, by its terms, did not permit such approach. Rule 34 of the Federal Rule of Civil Procedure requires a party to produce designated ESI.

See Fed. R. Civ. P. 34(a)(1)(A). The Federal Rules of Civil Procedure do not contain provisions regarding the use of email threading, nor do the Local Civil Rules of this Court.1 However, Rule

1 During the March 29 conference, Takeda argued that email threading was consistent with Rule 34(b)(2), which permits production “in a reasonably usable form or forms.” See Fed. R. Civ. P. 34(b)(2)(E)(ii). However, Rule 34(b)(2)(E)(ii) only comes into play if the form of production is not “otherwise stipulated or ordered by the court.” See Fed. R. Civ. P. 34(b)(2)(E). Here, the Discovery Protocol, which was approved by Judge Abrams, called for the production of ESI in native format, together with the metadata and coding fields set forth in Exhibit 1 to the Protocol, and did not permit the exclusion of any ESI or metadata from production. (See Discovery Protocol at 6-7 & Ex. 1.) In addition, as the Advisory Committee Notes to the 2006 Amendments to Rule 34 make clear, where “the responding party ordinarily maintains the information it is producing in a way that makes it searchable by electronic means, the information should not be produced in a form that removes or significantly degrades this feature.” See Fed. R. Civ. P. 34, Adv. Comm. Notes, 2006 Amend. In the present case, by performing threading, Takeda has degraded Plaintiffs’ ability to conduct searches of the emails for senders and recipients, as discussed below. 29 of the Federal Rules of Civil Procedure permits the parties to stipulate to procedures governing discovery, see Fed. R. Civ. P. 29(b), for example, by use of discovery protocols. Indeed, the Sedona Principles2 encourage the parties to have “early discussions” regarding “procedural issues

relating to the form of production,” and to enter into an “agreed upon protocol governing the production of ESI and avoid downstream misunderstandings or disputes.” See The Sedona Principles, Third Edition: Best Practices, Recommendations & Principles for Addressing Electronic Document Production, 19 Sedona Conf. J. 1, Comment 3.c. (2018) (hereinafter, “Sedona Elec. Doc. Prod. Principles”), available at https://thesedonaconference.org/publications (italics omitted); see also id., Comment 12.b. (“Ideally, the form or forms used for production of ESI should be

agreed upon early.” (italics omitted)). It is not uncommon for ESI protocols to address the use of email threading. As Takeda notes, such protocols have been entered in cases in this Court. (See Defs.’ 3/25/22 Opp.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
In re ACTOS Antitrust Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-actos-antitrust-litigation-nysd-2022.